Tenderwize
Zurück zur Suche

Non-exclusive agreement for fremanezumab medicines

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Mar 31, 2028 · 583 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Fremanezumab (ATC-Code: N02CD03) im Wege eines Open-House-Modells

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

52 / 100

Komplexität

58 / 100

Risikofaktoren

The exact submission instructions and all deadlines are said to be contained in project-room documents that were not pr...

Only pharmaceutical undertakings within the meaning of section 4(18) AMG may participate, and local representatives qua...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Supply of pharmaceutical products containing the active substance fremanezumab (ATC code N02CD03).
  • Open-House participation model for non-exclusive contractual arrangements.
Vollständige Zusammenfassung anzeigen

This is an Open-House supply arrangement for pharmaceutical products containing fremanezumab (ATC N02CD03), led by AOK PLUS. It is non-exclusive, open to all interested pharmaceutical companies that meet and accept the participation conditions. No individual negotiations or guaranteed minimum purchase volumes are provided. Participation documents must be obtained via DTVP after access approval, and participation requests are submitted electronically through the portal communication function. The arrangement runs until 31 March 2028 at the latest. The notice contains several technical/formal fields that are stated to have no substantive legal meaning for this Open-House procedure.

Risiken

The exact submission instructions and all deadlines are said to be contained in project-room documents that were not pr...

Only pharmaceutical undertakings within the meaning of section 4(18) AMG may participate, and local representatives qua...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical company within the meaning of the notice.

Eligibility

  • The declaration on non-existence of exclusion grounds must be completed and submitted.

Administrative

  • Participation conditions in the documents must be accepted.

Auftraggeber

Ort

Erfurt, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE256878834

Tätigkeit

Health

Lose (1)

LOT-0001

Non-exclusive agreement for fremanezumab medicines

Open-House supply arrangement for medicines containing fremanezumab (ATC N02CD03). The lot is described as a non-exclusive agreement open to all interested pharmaceutical companies that satisfy the participation conditions. No minimum purchase quantity is guaranteed and demand is stated to be unknown. Place of performance is Dresden, Germany, with broader reference to Germany / Saxony / Thuringia in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Ort

Dresden, Germany

Dauer

Mar 2026 - Mar 2028

Kategorie

Pharmaceutical products

Frist

Deadline Mar 31, 2028

Vergabedetails

Veröffentlichungsdatum
05 Feb 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
88189-2026

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3